Fig. 1

In the derivation cohort, patients with monocyte count ≥ 0.60 K/μL presented with significantly lower median FVC%pred than patients with monocyte count < 0.60 K/μL [75.0, (95% CI 71.3–76.7) vs. 80.9, (95% CI 77.5–83.1), (P = 0.01)] (a). In the validation cohort, median FVC%pred was 72.4 (95% CI 68.8 to 79.6) and 79.5 (95% CI 72.9–82.9) for patients with baseline monocyte count ≥ 0.60 K/μL and < 0.60 K/μL, respectively, (P = 0.09), (b). In the derivation cohort, patients with monocyte count ≥ 0.60 K/μL presented with significantly lower median DLCO%pred than patients with monocyte count < 0.60 K/μL [47.5, (95% CI 44.3–52.3) vs. 53.0, (95% CI 48.0–56.7), (P = 0.02)] (c). The same cut-off threshold had similar discriminatory value in the validation cohort [median DLCO%pred for patients with baseline monocyte count ≥ 0.60 K/μL: 37.8, (95% CI 35.5 to 41.1) vs. median DLCO%pred for patients with baseline monocyte count < 0.60 K/μL: 45.5, (95% CI 41.9 to 49.4), (P < 0.001), (d)]